Platelet Hemostatic Capacity (PHC) and Fibrinolytic Inhibitors during Pregnancy

Publisher Website
Google Scholar
Abstract
Platelet hemostatic capacity (PHC) was measured in blood from pregnant patients during all three trimesters using the PFA-100™ system. Closure times were shorter with both cartridge systems during pregnancy, compared to non-pregnant controls, suggesting increased PHC. Thrombin/antithrombin (TAT) complex and prothrombin fragment 1 + 2 (F1+2) levels were elevated during pregnancy and increased over time. Also, plasma levels of plasminogen activator inhibitor 1 and 2 (PAI-1, PAI-2) increased during pregnancy. The data suggest increased coagulability during pregnancy. It is suggested that estrogen may play a role in this state of hypercoagulability. Seven days after delivery all of the measured parameters, except TAT levels, were again within normal range.

This publication has 0 references indexed in Scilit: